Develops drugs for rare diseases and cancer.
Jun 2026Revenue $54.9M/yrExpenses $599M/yr
No trendCash runway ≈ 1.5 years from Jun 2026
Figures by year
When will Recursion Pharmaceuticals be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $54.9M and expenses $599M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $74.7M | $723M | −$648M |
| Dec 2024 | $58.8M | $538M | −$479M |
| Dec 2023 | $44.6M | $395M | −$350M |
| Dec 2022 | $39.8M | $286M | −$246M |
| Dec 2021 | $10.2M | $193M | −$183M |
| Dec 2020 | $3.96M | $88.6M | −$84.6M |
| Dec 2019 | $2.32M | $64.8M | −$62.4M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.